doctors in training

Houston medical school presents inaugural class as construction begins on new building

The University of Houston broke ground on its new medical school building and named the College of Medicine's inaugural class. Photo via UH.edu

This month, the University of Houston has taken a couple huge steps toward establishing a prestigious medical school program — the first new medical school to be established in Houston in almost 50 years.

UH has broken ground on its $80 million medical school building that is expected to be completed in 2022, and the program has named its inaugural class.

The new cohort of future doctors is a group diverse in ethnic background and life experience. The school plans to tackle a key issue in public health: the shortage of primary care doctors. These future doctors are charged by the university with eliminating health disparities in underserved urban and rural areas, which often have poorer health outcomes.

The UH College of Medicine received 1,728 applications for its first class of students; 164 applicants were interviewed for the 30 available spots, according to UH. An 18-member admissions committee screened those most likely to pursue primary care.

Here is a breakdown of UH's inaugural medical school class:

  • 30 students
  • 73 percent underrepresented minorities in medicine
  • 63 percent female
  • 57 percent first generation in college
  • 40 percent low socioeconomic status
  • 100 percent Texas resident
  • Five graduates of the University of Texas at Austin; two graduates each from the University of Houston, Baylor, Texas A&M, Houston Baptist, Prairie View A&M, and Rice University

According to the school, the goal is for 50 percent of graduates of the UH College of Medicine to choose primary care specialties including family medicine, general internal medicine, and general pediatrics. For some perspective, nationally, only about 20 percent of medical students choose primary care.

"We were very deliberate in our pursuit of medical students who fit the mission. This is much different than most other medical schools because we need different solutions for the current health care problems facing our city and state," said Dr. Stephen Spann, founding dean of the College of Medicine, in a statement.

Each student will receive a $100,000 four-year scholarship through philanthropy to cover tuition and fees. At full enrollment, the College of Medicine will have 480 students, per the school. The Health 2 Building in the UH Medical District will be the college's temporary home for the first two years until a new $80 million medical school building is completed in 2022. Construction crews broke ground on the new building on June 15, according to the university.

Being part of UH's inaugural medical school is deeply personal for students such as Cenk Cengiz. At 14, Cengiz's family emigrated from Turkey to Houston, but could not afford health insurance. Cengiz attended high school and college without ever seeing a doctor, which attracted him to the field of medicine and peaked his interest in the medical school's unique mission to help underserved communities.

"I came a long way from washing dishes at age 14 at a pizza store," Cengiz said in a statement. "My parents are super proud of me."

Dr. Stephen Spann is the founding dean of the College of Medicine. Photo via uh.edu

------

This article originally ran on CultureMap.

Trending News

Building Houston

 
 

You can now hop online and invest in this promising cell therapy startup. Photo via Getty Images

A clinical-stage company headquartered in Houston has opened an online funding campaign.

FibroBiologics, which is developing fibroblast cell-based therapeutics for chronic diseases, launched a campaign with equity crowdfunding platform StartEngine. The platform lets anyone — regardless of their net worth or income level — to invest in securities issued by startups.

The funding, according to a press release, will be used to support ongoing operations of Fibrobiologics and advance its clinical programs in multiple sclerosis, degenerative disc disease, wound care, extension of life, and cancer.

"We're excited to partner with StartEngine on this campaign. StartEngine has over 600,000 investors as part of their community and has raised over half a billion dollars for its clients," says FibroBiologics' Founder and CEO Pete O'Heeron, in the release.

"This is an exciting time at FibroBiologics as we continue progressing our clinical pipeline and developing innovative therapies to treat chronic diseases," he continues. "This new funding will fuel our growth in the lab and bring us one step closer to commercialization."

The campaign, launched this week, already has over 100 investors, at the time of publication, and has raised nearly $2 million, according to the page. The minimum investment is set at around $500, and the company's indicated valuation is $252.57 million.

In 2021, FibroBiologics announced its intention of going public. Last year, O'Heeron told InnovationMap on the Houston Innovators Podcast of the company's growth plans as well as the specifics of the technology.

Only two types of cells — stem cells and fibroblasts — can be used in cell therapy for a regenerative treatment, which is when specialists take healthy cells from a patient and inject them into a part of the body that needs it the most. As O'Heeron explains in the podcast, fibroblasts can do it more effectively and cheaper than stem cells.

"(Fibroblasts) can essentially do everything a stem cell can do, only they can do it better," says O'Heeron. "We've done tests in the lab and we've seen them outperform stem cells by a low of 50 percent to a high of about 220 percent on different disease paths."


Trending News